Anthem Biosciences' Q4 FY 2025-26 Quarterly Results

Result Summary

• Anthem Biosciences Ltd reported a 45.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 33.2%.
• Its expenses for the quarter were up by 28.1% QoQ and 20.8% YoY.
• The net profit increased 104.4% QoQ and increased 129.7% YoY.
• The earnings per share (EPS) of Anthem Biosciences Ltd stood at 3.34 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Anthem Biosciences Ltd is a company that operates within the biotechnology sector. The company is primarily engaged in the production and distribution of biosciences-related products and services. Although specific details about the company's product lines or recent developments are not provided, companies in this industry typically focus on the development of pharmaceuticals, high-end research and development (R&D) services, and possibly contract research and manufacturing services (CRAMS). Anthem Biosciences Ltd might be involved in similar activities given the sector it operates in. However, further details about its specific operations or recent strategic movements are not available within the provided data.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Anthem Biosciences Ltd reported a total income of ₹662.16 crores. This represents a significant increase of 45.0% compared to the third quarter of the same fiscal year (Q3FY26), where the total income was ₹456.68 crores. When compared year-over-year (YoY) with the fourth quarter of the fiscal year 2025 (Q4FY25), which saw a total income of ₹497.26 crores, there is a growth of 33.2%. The revenue figures indicate robust growth both on a quarterly and annual basis, highlighting a period of increased income generation for the company.

Profitability

The financial performance in terms of profitability for Anthem Biosciences Ltd shows notable growth. The Profit Before Tax (PBT) for Q4FY26 was ₹277.92 crores, an increase of 113.0% from the previous quarter (Q3FY26), which recorded a PBT of ₹130.47 crores. Compared to the same quarter in the previous year (Q4FY25), which had a PBT of ₹178.31 crores, there was a growth of 55.9%. After accounting for taxes, the Profit After Tax (PAT) for Q4FY26 was ₹189.76 crores, which marks a 104.4% increase from Q3FY26 and a substantial 129.7% increase YoY from Q4FY25. The Earnings Per Share (EPS) for Q4FY26 was ₹3.34, showing a 103.7% increase QoQ from ₹1.64 in Q3FY26 and a 127.2% increase YoY from ₹1.47 in Q4FY25. These metrics reflect a strong profitability trend during the period under review.

Operating Metrics

Anthem Biosciences Ltd's operating metrics for Q4FY26 indicate a total expense of ₹385.22 crores, which reflects a 28.1% increase from Q3FY26, where total expenses were ₹300.83 crores. Compared to Q4FY25, where total expenses were ₹318.94 crores, there is an increase of 20.8% YoY. The tax expense for Q4FY26 was ₹88.16 crores, marking a significant 134.1% increase from the previous quarter's tax expense of ₹37.66 crores, while showing a slight decrease of 7.9% compared to Q4FY25, which was ₹95.69 crores. The increase in expenses, along with the growth in income, suggests scaling operations within the company during this period.